Pages that link to "Coronary stent thrombosis"
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
(List of links)
> Coronary stent thrombosisThe following pages link to Coronary stent thrombosis:
View (previous 50) (next 50) (20 | 50 | 100 | 250 | 500)- Stent Thrombosis (redirect page) (← links)
- Today in Medicine: Study Shows Favorable Long-Term Outcomes for DES Implantation in Unprotected Left-main Lesions (← links)
- Today in Medicine: Mixed Long-term Results for Sirolimus-Eluting Stent Implantation in Diabetic Patients (← links)
- Management of specific types of coronary lesions (← links)
- Almost two years after implantation, Sirilimus-eluting coronary stents remain exposed to the circulation. August 11, 2007 (← links)
- Incidence of stent thrombosis in BMS (← links)
- Incidence of stent thrombosis in DES (← links)
- The WikiDoc Living Textbook of Cardiology (← links)
- Definitions of coronary stent thrombosis (ST) (← links)
- Stent thrombosis definitions (← links)
- Stent thrombosis incidence in drug eluting stents (← links)
- Stent thrombosis incidence in bare metal stents (← links)
- Stent thrombosis relationship to discontinuation of antiplatelet therapy (← links)
- Stent thrombosis mechanism and pathophysiology (← links)
- Interventional Cardiology (← links)
- Testlist (← links)
- Testlist2 (← links)
- Jacko test (← links)
- User:Jacki Buros/all cardiology (← links)
- Stent thrombosis (redirect page) (← links)
- Antiplatelet therapy (← links)
- High recurrence rate of stent thrombosis after the first event: Results from the Dutch Stent Thrombosis Registry (← links)
- High Dose Tirofiban is similar to Abciximab in reducing Major Adverse Cardiac Events (← links)
- Excel biodegradable stents are safe and effective: Results from the CREATE trial (← links)
- The Efficacy of XIENCE V Stent over Taxus Stent Decreases with Time: Results from the SPIRIT II study (← links)
- CoStar Drug Eluting Stent is not Non-inferior to TAXUS Drug Eluting Stents (← links)
- NOBORI™ stent is non-inferior to Taxus® stents in the NOBORI 1 trial (← links)
- Xience V stent continues to demonstrate superior efficacy over the Taxus stent up to 2 years in the SPIRIT III trial (← links)
- Landmark analysis of the TRITON-TIMI 38 trial demonstrates significant benefit with the loading and maintenance doses of prasugrel (← links)
- Bivalirudin during primary PCI reduces major bleeding and adverse events at 30 days in the HORIZONS-AMI trial (← links)
- Unprotected Left Main Stem PCI with Drug Eluting Stents is Associated with Favorable Long-term Outcomes (← links)
- Drug Eluting Stents Continue to Demonstrate Superiority over Bare Metal Stents in Reducing the Need for Repeat Revascularization (← links)
- Biolimus Eluting Stents Shown to be as Safe and Effective as Sirolimus Eluting Stents in Everyday Clinical Practice: Results from the LEADERS Trial (← links)
- Late stent thrombosis (redirect page) (← links)
